FUTURELAND CORP. (OTCMKTS:FUTL) Files An 8-K Completion of Acquisition or Disposition of Assets

FUTURELAND CORP. (OTCMKTS:FUTL) Files An 8-K Completion of Acquisition or Disposition of Assets
Item 2.01, Completion of Acquisition or Disposition of Assets

Story continues below

On September 15, 2017, the Company purchased 20% of Apotheca Biosciences, Inc. for an undisclosed amount. Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Their pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.

Apotheca Earth Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures our focus on customer wellbeing.

The acquisition of Apotheca Biosciences will close the loop for FutureLand Corp to have a stake in a growing cutting-edge medical products in the fastest growing CBD market within the cannabis industry. The acquisition will create great value for the company and its shareholders. Apotheca Biosciences is considering an IPO in coming weeks.


About FUTURELAND CORP. (OTCMKTS:FUTL)

FutureLand, Corp., formerly known as AEGEA, Inc., operates its business through its subsidiary, FutureLand Properties LLC. FutureLand Properties LLC is an agricultural land lease company catering to the industrial hemp, legal medical marijuana and recreational cannabis market. The Company focuses on approximately 240 acres of prime property in southern Colorado. The Company has other developmental land use plans for other projects being pursued as well. The Company has not generated any revenues.

An ad to help with our costs